Wisconsin Alumni Research Foundation

Technology

Provoking Anti-Tumor Immune Response with Rhamnose

One promising approach to cancer treatment is to leverage the immune system. Specifically, tumors can be ‘tagged’ with foreign antigens that attract the body’s defensive antibodies. The antibodi...
Learn More
Laura Kiessling, Rachael Sheridan, Jonathan Hudon | P120290US02

Technology

Vitamin D Analogs for Treating Bone Cancers and Diseases

The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Izabela Sibilska-Kaminski, Rafal Sicinski | P100358US03

Technology

Vitamin D Analog for Cancer Prevention and Treatment

The hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone...
Learn More
Hector DeLuca, Katarzyna Barycka, Katarzyna Plonska-Ocypa, Rafal Barycki, Lori Plum, Margaret Clagett-Dame, Izabela Sibilska-Kaminski, Rafal Sicinski | P100077US02

Technology

Prostate Cancer and Melanoma Screening

Almost 200,000 men in the United States develop prostate cancer each year. More than 60,000 people develop melanoma. Early diagnosis is key to survival because the best treatment and prognosis for the...
Learn More
Douglas McNeel, Edward Dunphy, Jason Dubovsky, Luke Hoeppner | P06004US

Technology

Cytotoxic Ribonuclease Variants

Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Ronald Raines, George Phillips, R. Jeremy Johnson, Jason McCoy | P05341US

Technology

Cytotoxic Ribonuclease Variants

Ribonucleases are enzymes that catalyze the degradation of RNA. Levels of RNase activity are controlled in vivo by a ribonuclease inhibitor (RI), which binds strongly to an RNase to completely inhibit...
Learn More
Ronald Raines, Julie Mitchell, Thomas Rutkoski | P04427US

WARF